Dr David Samadi, chief robotic surgery at Lenox Hill Hospital, is a urologic surgeon specialized in laparoscopic, open, robotic and oncology surgeries. He was born and raised in a Jewish community in Iran. In 1982, during the Iranian revolution, he and his brother moved to London and Belgium six months later. His parents would not accompany them because of the Jewish traditions, and his small sister too was so young to be left under his care. Later, his parents arranged to move to a certain school in America where they had paid for their (David and his brother) stay. They stayed in a boarding school and graduated, joined high school and with the completion of high school David joined Stoney brook school of medicine and majored in biochemistry. He also studied in Montefiore Medical Centre where he studied general surgery.
He also has knowledge in urology acquired in Albert Einstein medical school, robotic prostatectomy from Henri Mondor Hospital in France and oncology, urology fellowship at Memorial Sloan Kettering Cancer Centre.# Currently, Dr David Samadi is a great and magnificent surgeon and doctor who has specialized in prostate cancer. He performs an average of 15 prostate cancers surgeries per week to many people around the world. One of his patients was Mitt Romney, a previous presidential nominee of the Republican Party. Dr David Samadi announced that Romney was diagnosed with common and curable prostate cancer and following surgery, he was successfully treated. He is much experienced in prostate cancer treatment with robotic laparoscopic surgeries, the newest technological methods in the world of medicine.
He has performed many robotic prostate surgeries to over 7000 patients, and he stands to be the first prostate surgeon to perform the SMART technique in surgery using da Vinci system, a system designed to perform surgeries that are complex and involves fewer body invasions controlled by a surgeon. Dr David Samadi has won several awards including, New York super doctor in 2014, most empathetic doctor in 2011, Top Americas doctor 2008-2013, the America top doctor in the cancer field, selected by New York magazine as the best doctor in 2009-2012 and 2015. The magazine also selected him as the top 1251 doctors in the state in 2013-2014.In an interview with Idea mensch, he said that he believes that there is future in robotics and medical integration and he encourages technologist to venture more into the field.
Oncotarget is a publishing company that publishes journals and distributes them on their online platform. Access to these publications is for free for all the websites clients. The releases are usually made on a weekly basis depending on the demand for the particular journals. Trending issues and topics at times determine the journal that will be published on Oncotargets website. The journals availed for its readers tend to cut across various disciplines hence the reason why the site is referred to as multidisciplinary. Over the years, Oncotarget has been striving to maximize the potential impact its published materials have on its audience while at the same time providing an insightful view to current issues within the scientific realm.
There has been an ongoing urgency by Oncotarget to abolish the boundaries within the biomedical specialties.With the leadership of the renowned scientists, Oncotarget has been providing researchers with journals that are aimed at contributing significantly to the development of sciences to one day achieve a life free from diseases.Oncotarget has been liaising closely with exemplary high-profile scientific indexes with the aim of providing all relevant scientific publications robustly to its clients. This has been well demonstrated by the collaboration between Oncotarget and IntegraGen.IntegraGen is a firm that has over the years specialized in the transformation of samples of biological data to genomic information and at times diagnostic equipment for Oncology.
Recently, news of the publishing of the analysis of tumor samples from patients who were undergoing the NEW EPOC clinical trial surfaced. Research carried out by IntegraGen show of a relationship between miR-31-3p expression and anti-EGFR treatment. There is the need to develop a tool that is capable of distinguishing patients who can benefit from this treatment option from those who can’t.As a business, Oncotarget doesn’t plan on being left behind with the 21st century’s technological wave. Currently, the firm is adopting new indexing algorithms aimed at the facilitation of dissemination of their scholarly Journals to relevant personnel within the sizeable medical research factions. Due to the increasing demand for Oncotargets journals, the company has shifted from publishing journals to their website one a week to the current rate of two Journals each week.
Making contributions to propel never-before-seen research when it comes to the field of cutting-edge medicine at the Rutgers Cancer Institute which is located in New Jersey. Omar Boraie was recently awarded a newly-appointed chair that was named in his honor. Named the Omar Boraie Chair in Genomic Science, this endowed chair is considered the gold standard in higher education. It also expresses the commitment of a university to concentrate on an academic discipline at the highest levels to ensure its continued progression and support.
According to Yahoo.com, New Brunswick developer Omar Boraie was included in the 18 Chair Challenge, where an anonymous donor must match a $1.5 million support campaign at Rutgers University. The university formed 18 new chairs which included the New Jersey developer. The new Omar Boraie chair will help carve a new path for new discoveries in precision medicine and genomic science.
A Growing Field of Study
The field of genomic science and precision medicine has made profound changes on how professionals who work in the medical field approach how cancer is diagnosed and treated. This field is relatively new says the NY Times and involves tumor analysis and treatment using techniques that give doctors that opportunity to help patients at the genetic level. These analyses and treatments allow doctors to prescribe therapies that are individualized for each patient which result in better outcomes.
Rutgers at the Forefront
As one of the first medical treatment centers in the country as well as New Jersey to apply for genomic sequencing as a primary approach to patient care, Rutgers Cancer Institute remains a leader in performing advanced gene sequencing on tumors as a part of ongoing research at the university. For those who have rare cancer diseases or poor prognoses will highly benefit from this research. In addition, many people have treatment options which have been infected or limited, so genomic sequencing has been extremely helpful in finding unique therapies that were not available to patients with such circumstances in the past.
Recently Quoted on Newswise
In a recent article from Newswise (http://newswise.com/articles/omar-boraie-chair-in-genomic-science-established-at-rutgers-cancer-institute), Omar Boraie mentioned that physicians and scientists at Rutgers Cancer Institute are making huge advances precision medicine, especially for patients who are suffering from cancers that are no longer responsive. He also expressed that he is hopeful that the money he put forward will help others. In addition, he encouraged others to become an anonymous donor for the 18 Chair Challenge. He also hopes his family’s pledge to support the Rutgers Cancer Institute will inspire others to contribute as well. Boraie has been a long supporter of cancer research and this endowment furthers his vision to develop New Brunswick into a “Healthcare City”.